Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KUR-101 in healthy adults
NCT05114265Phase 1Completed
- Sponsor
- Kures Therapeutics
- Start
- Feb 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Deumitragynine in acute pain and opioid use disorder (OUD) (2 arms), sponsored by Kures Therapeutics. Primary endpoints: Safety of KUR-101 when compared with placebo at Day 15 and Effect of KUR-101 on evoked pain response as compared to oxycodone and placebo. Started Feb 2022; status: completed.
02
Drugs
Deumitragynine
03
Conditions
acute painopioid use disorder (OUD)
Beyond the preview
Go deeper on NCT05114265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05114265.